A Novel Cause of Familial Hypercholesterolemia: PCSK9 Gene Duplication

被引：3

作者：

Paquette, Martine ^{[1
]}

Baass, Alexis ^{[1
,2
,3
]}

机构：

[1] Montreal Clin Res Inst, Lipids Nutr & Cardiovasc Prevent Clin, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada

[2] McGill Univ, Div Expt Med, Dept Med, Montreal, PQ, Canada

[3] McGill Univ, Div Med Biochem, Dept Med, Montreal, PQ, Canada

来源：

CANADIAN JOURNAL OF CARDIOLOGY | 2018年 / 34卷 / 10期

关键词：

AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA; DENSITY-LIPOPROTEIN RECEPTOR; MUTATIONS;

D O I：

10.1016/j.cjca.2018.08.027

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1259 / 1260

页数：2

共 50 条

[41] Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
Cunningham, David
Danley, Dennis E.
Geoghegan, Kieran F.
Griffor, Matthew C.
Hawkins, Julie L.
Subashi, Timothy A.
Varghese, Alison H.
Ammirati, Mark J.
Culp, Jeffrey S.
Hoth, Lise R.
Mansour, Mahmoud N.
McGrath, Katherine M.
Seddon, Andrew P.
Shenolikar, Shirish
Stutzman-Engwall, Kim J.
Warren, Laurie C.
Xia, Donghui
Qiu, Xiayang
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (05) : 413 - 419
[42] Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
Tandirerung, Fistra Janrio
CARDIOVASCULAR DRUGS AND THERAPY, 2023, 39 (2) : 405 - 413
[43] Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
Tandirerung, Fistra Janrio
CARDIOVASCULAR DRUGS AND THERAPY, 2023,
[44] A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia
Brandts, Julia
Dharmayat, Kanika, I
Vallejo-Vaz, Antonio J.
Sharabiani, Mansour Taghavi Azar
Jones, Rebecca
Kastelein, John J. P.
Raal, Frederick J.
Ray, Kausik K.
ATHEROSCLEROSIS, 2021, 325 : 46 - 56
[45] The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
Meshkov, Alexey
Ershova, Alexandra
Kiseleva, Anna
Zotova, Evgenia
Sotnikova, Evgeniia
Petukhova, Anna
Zharikova, Anastasia
Malyshev, Pavel
Rozhkova, Tatyana
Blokhina, Anastasia
Limonova, Alena
Ramensky, Vasily
Divashuk, Mikhail
Khasanova, Zukhra
Bukaeva, Anna
Kurilova, Olga
Skirko, Olga
Pokrovskaya, Maria
Mikova, Valeriya
Snigir, Ekaterina
Akinshina, Alexsandra
Mitrofanov, Sergey
Kashtanova, Daria
Makarov, Valentin
Kukharchuk, Valeriy
Boytsov, Sergey
Yudin, Sergey
Drapkina, Oxana
GENES, 2021, 12 (01) : 1 - 17
[46] Qualitative and Quantitative Effects of PCSK9 Inhibitors in familial Hypercholesterolemia: a Synthetic Review
Shakir, Aamina
Barron, Kyle
Modi, Kalgi
CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (04)
[47] Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk
Saavedra, Yascara G. Luna
Dufour, Robert
Baass, Alexis
JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (06) : 786 - 793
[48] Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham
Dennis E Danley
Kieran F Geoghegan
Matthew C Griffor
Julie L Hawkins
Timothy A Subashi
Alison H Varghese
Mark J Ammirati
Jeffrey S Culp
Lise R Hoth
Mahmoud N Mansour
Katherine M McGrath
Andrew P Seddon
Shirish Shenolikar
Kim J Stutzman-Engwall
Laurie C Warren
Donghui Xia
Xiayang Qiu
Nature Structural & Molecular Biology, 2007, 14 : 413 - 419
[49] PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all
Stein, Evan A.
CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (05) : 427 - 431
[50] Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia
Pisciotta, Livia
Oliva, Claudio Priore
Cefalu, Angelo Baldassare
Noto, Davide
Bellocchio, Antonella
Fresa, Raffaele
Cantafora, Alfredo
Patel, Dilip
Averna, Maurizio
Tarugi, Patrizia
Calandra, Sebastiano
Bertolini, Stefano
ATHEROSCLEROSIS, 2006, 186 (02) : 433 - 440

← 1 2 3 4 5 →